Given the likelihood that some patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.
Last reviewed on RxList: 1/14/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Navane Information
Report Problems to the Food and Drug Administration
Get tips on therapy and treatment.